Lv1
70 积分 2025-07-21 加入
Time from suspected thrombotic thrombocytopenic purpura to initiation of plasma exchange and impact on survival: A 10-year provincial retrospective cohort study
10天前
已完结
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
20天前
已完结
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
21天前
已完结
[Chinese expert consensus on the follow-up management of patients with prostate cancer receiving medical castration therapy（2024 edition）]
1个月前
已完结
Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need
1个月前
已完结
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia
1个月前
已关闭
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial
1个月前
已完结
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
1个月前
已完结
Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer
1个月前
已完结
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
1个月前
已完结
皖公网安备34019202002308
